focus -WSS

focus

author：comprehensive 2025-09-29 01:09:30 - browse：4

Adobe

The federal government inappropriately lowered the 2024 Medicare Advantage star ratings of SCAN Health Plan, which led to the health insurance company in California losing hundreds of millions of dollars in bonuses from the government, a judge ruled Monday.

The decision will lead to more than $250 million funneling back into SCAN, which covers 270,000 Medicare Advantage enrollees. And it opens the door for other Medicare Advantage plans to potentially recoup huge sums of taxpayer-funded bonuses — even though many independent experts believe the quality rating system is flawed and doesn’t appropriately gauge quality of care for older adults and people with disabilities.

The Centers for Medicare and Medicaid Services, the federal agency that oversees all Medicare programs, said it does not comment on litigation. In an interview, SCAN CEO Sachin Jain told STAT that if the company had not gotten its expected bonus money, it would have had to shave benefits and reduce what it pays hospitals and doctors.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Three issues to watch in global health in 2024

explore

WSS

Cancer drug shortages should be causing more outrage

New Medicare drug pricing powers could soon be upended in court

Apple is now the first public company to be valued at $3 trillion

Heart attack and stroke risk calculators need revising

Virginia high school admissions case could be legal follow

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Wikipedia

Hollywood unions extend contract negotiations for actors

JPM 2024: Nvidia claims we're in biological revolution. Are we?

The cancer drug shortage isn’t new — and neither are the solutions

Caregivers of transplant patients call for more support, training

New air purifier tech could be key to improving indoor air quality

Risky weight loss products often used by teens globally, per study

Heart attack and stroke risk calculators need revising

Duchenne breakthrough therapy leaves behind pioneering families

Heart attack and stroke risk calculators need revising

JPM 2024: Nvidia claims we're in biological revolution. Are we?

focus

Hepatitis C has a cure — but many Americans still lack access to it

Cancer drug shortages should be causing more outrage

Cancer drug shortages should be causing more outrage

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Psychedelics group wrestles with new pharma identity

Virginia high school admissions case could be legal follow

leisure time

knowledge

explore

explore